secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001193125-23-269869
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf announces preliminary Phase 1/1b data for WTX-124 showing proof of mechanism and early antitumor activity
--------------------------------------------------------------------------------

- 16 heavily pretreated patients in first four monotherapy dose cohorts (1-12 mg); no dose-limiting toxicities or VLS observed.
- Two unconfirmed partial responses at 12 mg; one additional patient with evidence of antitumor activity.
- CD8+ T and NK cell proliferation/activation in tumor microenvironment seen at 6 mg and 12 mg.
- Dose escalation ongoing; cohort 5 (18 mg) fully enrolled; RDE and expansion arms expected H1 2024.
- WTX-124 generally well-tolerated in outpatient setting with all TEAEs Grade 1-2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000119312523269869/0001193125-23-269869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000119312523269869/d503964d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-269869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer